IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.800
+0.080 (4.65%)
Mar 9, 2026, 1:21 PM EDT - Market open
IN8bio Employees
IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.
Employees
18
Change (1Y)
-13
Growth (1Y)
-41.94%
Revenue / Employee
n/a
Profits / Employee
-$1,215,176
Market Cap
17.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| Serina Therapeutics | 13 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Allarity Therapeutics | 7 |
| Intensity Therapeutics | 7 |
| Quoin Pharmaceuticals | 5 |
| Pasithea Therapeutics | 4 |
INAB News
- 13 days ago - IN8bio to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 weeks ago - IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer - GlobeNewsWire
- 4 weeks ago - IN8bio to Present at Upcoming Investor and Scientific Conferences in February - GlobeNewsWire
- 2 months ago - IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma - GlobeNewsWire
- 2 months ago - IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager - GlobeNewsWire
- 4 months ago - IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewsWire
- 4 months ago - IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications - GlobeNewsWire